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Abstract
Background
Nyaditum resae® (NR) is a galenic preparation of heat-killed Mycobacterium manresensis, a
new species of the fortuitum complex, that is found in drinkable water, and that has demon-
strated to protect against the development of active TB in a murine experimental model that
develop human-like lesions.
Methods
Double-blind, randomized, placebo-controlled Clinical Trial (51 volunteers included). Two
different doses of NR and a placebo were tested, the randomization was stratified by Latent
Tuberculosis Infection (LTBI)-positive (n = 21) and LTBI-negative subjects (n = 30). Each
subject received 14 drinkable daily doses for 2 weeks.
Results
All patients completed the study. The 46.3% of the overall reported adverse events (AE)
were considered related to the investigational treatment. None of them were severe (94%
were mild and 6% moderate). No statistical differences were found when comparing the
median number of AE between the placebo group and both treatment groups. The most
common AE reported were gastrointestinal events, most frequently mild abdominal pain
and increase in stool frequency. Regarding the immunogenic response, both LTBI-negative
and LTBI-positive volunteers treated with NR experienced a global increase on the Treg
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response, showed both in the population of CD25+CD39-, mainly effector Treg cells, or
CD25+CD39+ memory PPD-specific Treg cells.
Conclusion
This clinical trial demonstrates an excellent tolerability profile of NR linked to a significant
increase in the population of specific effector and memory Tregs in the groups treated with
NR in both LTBI-positive and negative subjects. NR shows a promising profile to be used to
reduce the risk of active TB.
1 Introduction
Tuberculosis is one of the most frequent infectious diseases in the world, in spite of being a
curable disease [1]. Even if a vaccine (Bacille Calmette Gue´rin -BCG-) has been available since
1927 and extensively used (3 billion doses used), there is a consensus that it only helps to stop
the development of disseminated and meningeal TB [2]. In fact it has been experimentally
demonstrated that BCG vaccination stops the bacillary growth in vaccinated subjects sooner
than in the unvaccinated, but does not avoid the infection by Mycobacterium tuberculosis
(Mtb) [3].
One of the characteristics of Mtb infection, is that it is transmitted through aerosol and that
disease is not usually the immediate consequence of the infection [4], resulting in LTBI, were
the bacilli is able to remain in the subjects for a long period, even years. It has been estimated
that approximately a third of mankind already has LTBI [5] without hindering the host.
Lesions of 1 mm in diameter at the lung parenchyma are irrelevant to challenge normal lung
function [6], which is why most of them ignore the fact of being infected. The only way to
know that someone has LTBI is by performing the tuberculin skin test (TST) or the T-cell
interferon-gamma release assays (TIGRA) [7]. A low percentage (around 10%) will develop
active TB (TB) [5], and besides severe immunodeficiencies (like AIDS) [1], the mechanism of
other comorbid factors are poorly known.
A new theory supported by experimental data and published recently suggests that the
development of active TB is caused by an exaggerated response against Mtb. This response is
based on a progressive massive neutrophilic infiltration of the lesions (causing a sudden
increase in size) and with the presence of nearby coincident lesions; a process favoured by the
environment of the upper lobes, that leads to the coalescence of the lesions [8,9]. This mecha-
nism could also explain why subjects with diabetes mellitus (DM) have 3 times more risk to
develop TB [10,11]. DM is a consequence of an imbalance in the Treg/Th17 response [12],
generating a global exaggerated inflammatory response.
An excessive inflammatory response in LTBI would be materialized through a neutrophilic
infiltration fuelled by Th17 cells, stimulated by the Mtb infection itself in an intensity that
depends on the host reactivity [13]. It has been demonstrated that in subjects with LTBI there
is an inverse relation between the Th17 and Treg cells [14]; and that Th17 response can be
counterbalanced by the presence of Tregs [15–17]. In this context, we decided to induce a Treg
response through a low dose tolerance process using heat-killed Mtb (HKMtb) cells, and sev-
eral environmental mycobacteria for their cross-immunity with Mtb [18], with successful
results. Among the environmental mycobacteria tested, a species usually found in drinking
water and thus able to be considered as a food supplement [19] was isolated. It was identified
to be part of the fortuitum complex, according to a state-of-the-art multiplex probe assay [20]
Safety and immunogenicity of the supplement food Nyaditum resae®
PLOS ONE | DOI:10.1371/journal.pone.0171294 February 9, 2017 2 / 20
IFI14/00015 (PC); and Manremyc sl. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: "Inactivated mycobacteria for
oral use in the prevention of tuberculosis” is a
patent (PCT/ES2013/000145) owned by IGTP and
invented by PJC and CV. Manremyc sl is a new
spinoff from IGTP that has been created exclusively
for the development of this patent. PJC is the CEO
of this spin-off. This does not alter our adherence
to PLOS ONE policies on sharing data and
materials.
which is the standard for mycobacterium identification in clinical laboratories. After its
sequencing, it was considered a new species, called M. manresensis (Certificate of Deposit
CECT 8638 at the Spanish Type Culture Collection) [21]. This strain has been chosen to be
further developed as food supplement for its similar ability to induce the protection obtained
with HKMtb [22].
Oral administration of alive or heat-killed M. manresensis was found to stop the inflamma-
tory progression towards TB in an experimental murine model, a process linked to the
increase of PPD-specific memory Tregs (CD25+CD39+) [22]. This new tool that decreases the
risk of progression towards TB was patented by the Institut d’Investigacio´ Germans Trias i
Pujol (IGTP) (PCT/ES2013/000145) and transferred to a spin-off of the same Institute (Manre-
myc sl) for its development.
The study presented here is a pilot, double-blind, randomised, masked and placebo con-
trolled clinical trial (CT), conducted in volunteers, to evaluate the tolerability and the immu-
nogenicity of 2 oral doses of Nyaditum resae1 (a preparation of heat-killed M. manresensis)
administered daily for 14 days to the general population, both LTBI positive or negative.
2 Materials and methods
2.1 Ethics
The protocol of the study was reviewed and approved by the Ethics Committee at the investi-
gational centre (Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain). All
investigators and collaborators agreed to rigorously observe the Helsinki declaration with all
its amendments and to follow the Good Clinical Practice guidelines of the ICH (International
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use). The objectives and methodology, as well as possible drawbacks and risks due
to the study, were explained to each subject orally and in writing (Subject Information Sheet)
before their inclusion. They were also informed of the different treatments to be tested, the
way they would be assigned to the groups, the option to withdrawal from the study at any time
and of the existence of an insurance contract. Informed consent was obtained of all the partici-
pating volunteers by consent form signature before starting any study procedure. Participants
were also informed and signed their consent to be included in a local register from the Health
Department of the Catalan Government to control the participation of healthy volunteers in
Phase I clinical trials. The trial has been registered in ClinicalTrials.gov: NCT02076139.
2.2 Participants
Subjects were interviewed and screened for enrolment at the Phase I Unit of the Hospital Ger-
mans Trias i Pujol (Badalona, Catalonia, Spain) by the clinical pharmacologists. The target
population of the study was healthy adults, with or without LTBI. A screening visit was made
for each volunteer where a complete anamnesis and physical exam, laboratory parameters tests
(hemato-biochemical and immunogenicity parameters), Tuberculin Skin Test (TST), serology
against HIV and a pregnancy test were performed. Previous TST was acceptable and was not
repeated when positive in the last 5 years or negative in the last 6 months. Radiological chest
X-ray exam was performed in TST-positive volunteers. Subjects were not included in the
study if any of the following criteria were present: TB, immunodeficiencies, chronic immuno-
suppressant therapy, reception of blood products or derivatives six months prior randomiza-
tion, pregnancy or lactation.
Furthermore, the investigator’s team certifies that to their knowledge all subjects were con-
sidered able to be included in the CT, in terms of fulfilling all the study’s requirements.
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2.3 Interventions
After the inclusion period, the volunteers were randomized in a proportion 1:1:1 to receive
either placebo or the Nyaditum resae1 (NR) in low (104) or high (105) doses, stratified by TST
status (Fig 1). The trial was originally designed to allocate 10 subjects per treatment group and
TST status. Once the groups with TST-negative were fulfilled, the screening process was
focused in looking for TST-positive subjects. NR was supplied by the sponsor (Manremyc S.L.,
Manresa, Catalonia, Spain) as a preparation of drinkable vials containing heat-killed Mycobac-
terium manresensis dissolved in distilled water. NR was produced under Good Manufacturing
Practice by the Laboratory Reig Jofre (Sant Joan Despı´, Catalonia, Spain). Placebo was identi-
cally supplied and formulated except that it only contained distilled water. Only a single batch
of both NR and placebo were used in the whole study. The distribution of the treatment vials
for the CT was carried out by the Clinical Research Organisation (CRO) of the study, Fundacio´
per la Lluita contra la Sida -FLS Research Support- (Badalona, Catalonia, Spain), where the
entire study treatment received was inventoried and accounted for throughout the study.
Once randomized, volunteers received a box with 14 drinkable vials with one of the 2 doses
of NR or Placebo at the Phase I Unit of the Clinical Pharmacology Department, supervised by
the Investigators and following the random plan specified in the study protocol. They drank
one vial every day at breakfast during 2 weeks.
Every subject included in the trial had the right to withdraw at any moment by immediately
contacting the investigators to inform them, without any obligation to provide reasons. This
participant was supposed to be replaced by another, except in the case the trial had to be ended
because of safety issues, and the new participant would have received the corresponding treat-
ment of the subject he or she replaced. If a participant was withdrawn because of an adverse
Fig 1. Chart representing the participant flow of the CT. From 76 people interviewed for eligibility, 51 could be included. All the 51 were randomized
and allocated to treatment, receiving it, being fully followed-up, and ending the trial and being analysed.
doi:10.1371/journal.pone.0171294.g001
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event, he or she would have been followed-up by the Investigators until resolution or reaching
a clinically stable endpoint. The investigators had the right to decide to terminate or suspend
the trial without prior agreement of the sponsor, by promptly informing the trial subjects
(assuring them appropriate therapy and follow-up), the sponsor and the regulatory authority.
2.4 Objectives
This trial aimed to evaluate 1) the global tolerability of the probiotic Nyaditum resae1 and 2)
the effect on specific memory regulatory T cells (Treg) cells population.
2.5 Outcomes
After the administration of the first drinkable vial, each volunteer was followed-up during 6
weeks. The monitoring plan (Table 1) shows every procedure of the follow-up planned during
the study.
The volunteers were monitored by the investigators team of the Phase I Unit in order to
perform the following safety evaluations: 1) record of adverse events, both gastrointestinal and
non-gastrointestinal, being reported by the subject either spontaneously or after questioning
or looking at the Volunteer’s Diary, during the first 4 weeks of the monitoring (Table 1); 2)
vital constants; 3) physical examination; 4) laboratory safety and immunogenicity tests.
Table 1. Chronogram and monitoring plan.
Selection Pre administration Administration Follow-up
Visit Selection Baseline w1 w2 w6
Day -28 -25 0 7 15 42
Week -4 -4 0 1 2 6
Window (days) ±14 0 ±3 ±3 ±3
Subject Information,
Informed consent
X
Inclusion/Exclusion criteria X X
Medical History X
HIV test X
Tuberculin Skin Test (TST) XA XB
Chest X ray XC
Pregnancy test in serum X X X
Randomization X
Treatment administration X
Physical exam and vital signs X X X X X
Biochemistry & Hematology X XD X X X
Immunogenicity sample X X X X
Volunteer diary* X X X XE
Concomitant medication X X X X X
Adverse events X X X X X
A Previous TST was acceptable and not repeated when positive in the last 5 years or negative in the last 6 months.
B TST readout.
C In the case of Positive TST.
D Not repeated if selection’s analysis performed in the previous 15 days.
E Collection of Volunteer’s Diary.
* Volunteer’s Diary records every day: day and hour of the treatment intake; stool deposition (number/day) and aspect (soft/hard); nausea (degree 1 to 3);
vomits (degree 1 to 3); abdominal pain (degree 1 to 3); other adverse events (degree 1 to 3). Degree 1: mild; degree 2: moderate; degree 3: severe.
doi:10.1371/journal.pone.0171294.t001
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AE detected by the investigator through interrogation or reported by the subject during
the defined period of collection were recorded. AE was considered as any unwanted medical
event in a subject in a clinical trial, regardless of its relationship with the intervention under
evaluation. A serious AE was defined as cause of death, life threatening, requiring inpatient
hospitalization, producing disability or incapacity persistent or significant or threatening
the patient. The investigators determined the relationship between the study treatment and
the AE as ‘not related’, ‘unlikely’, ‘possibly’, ‘probably’, and ‘definite’ according to a prede-
fined algorithm based on the modified Karch and Lasagna algorithm used by the Spanish
Pharmacovigilance System [23,24] and after a consensus reached between the clinical
pharmacologists study investigators. Laboratory abnormalities were graded following the
Toxicity Grading Scale Guidance provided by the Food and Drug Administration (FDA)
[25]. The main safety analyses have been focused on ‘possibly’, ‘probably’, and ‘definite’ clas-
sified AE.
Blood was extracted from the volunteers by the nurse of the Phase I Unit, under fasting con-
ditions and before any other procedure was done, at the time-points indicated in the chrono-
gram (Table 1). The samples were properly labelled and sent to the hospital laboratories for
laboratory safety testing (15 mL) and to the Experimental Tuberculosis Unit (UTE) (8 mL) for
the immunogenicity testing as soon as possible. The Departments involved in the safety labo-
ratory results (Haematology, Clinical Analysis and Microbiology) as well as the UTE, are
accredited by ISO 9001 procedures. The CRO of the study (FLS Research Support) monitored
all the study in order to ensure the use of standard terminology and the collection of accurate,
consistent, complete and reliable data.
Blood samples were tested for circulating cell counts (erythrocytes, leucocytes and plate-
lets), Hb, haematocrit, fasting glucose, aspartate aminotransferase, alanine aminotransferase,
g-glutamyl transpeptidase, alkaline phosphatase, total bilirubin, direct and indirect bilirubin,
urea N, creatinine, glomerular filtration rate, Na and K.
The reliability of the Immunogenicity data was ensured by the performance of all assays
always made by the same technician (previously trained during a 6 month period) and under
supervision. Accuracy of the performance of the techniques as well as the values obtained were
ensured by following strict specific procedures (Standard Operating Procedures SOPs) that
were previously designed and set up specifically for this CT and always under blinding prem-
ises. The sponsor also used an external auditing to review the following issues: data manage-
ment and statistics, both the UTE and the Phase I Unit, source data / source documents and
the Investigator File and the Trial Master File.
Measure of specific Tregs was done according to previous studies [14,26–28]. Peripheral
blood mononuclear cells (PBMC) were isolated in cell preparation tubes (CPT Becton Dickin-
son, BD) with sodium citrate according to the manufacturer proceedings, and processed
immediately. Protein Purified Derivative (PPD) batch 49 (Statens Serum Institute, Copenha-
gen, Denmark) was used alone at a final concentration of 10 μg/mL to measure antigen specific
responses. 1 x 106 cells/well were non-stimulated or PPD-stimulated in a complete medium
(RPMI-L-Gln, 10% heat-inactivated FCS, 10 U/ml penicillin, 10 U/ml streptomycin, 1 mM
sodium pyruvate, 0.025 mM 2-ME) for 7 days at 37˚C and 5% of CO2. The phenotypic analysis
was performed by flow cytometry, using the following antibodies for membrane staining:
PerCP-Cy 5.5 mouse anti-human CD3, APC-H7 mouse anti-human CD4, PE mouse anti-
human CD25 (BD Biosciences) and Brilliant Violet 421 mouse anti-human CD39 (BioLe-
gend). Data acquisition was performed using an LSRFortessa flow cytometer (BD Biosciences)
and analysed with FACSDiva software (BD Biosciences) (Fig 2).
None of the Immunogenicity assessments performed in the present CT were standard pro-
cedures. As no cut-off exists for those non-validated and research-only techniques, a statistical
Safety and immunogenicity of the supplement food Nyaditum resae®
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Fig 2. FACS analysis strategy used allowed us to find 4 different types of populations. CD25+CD39-: mainly effector
Tregs (80–90%) [29]; CD25+CD39+: memory Tregs [26]; CD25-CD39-: Non Treg Effector cells; CD25-CD39+: ex-Treg cells
mainly IL-17 producers [26].
doi:10.1371/journal.pone.0171294.g002
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difference (p<0.05) between the time-points among the same treatment group has been con-
sidered enough to prove the reactivity of the treatment.
2.6 Sample size
Given that this clinical trial was an exploratory study of the first administration in humans,
basically intending to demonstrate the safety of the probiotic, a formal predetermination of
sample size based on numeric or statistic criteria was not made. In any case, the numbers shuf-
fled in the trial (51 subjects, 18 placebo and 33 of treatment) were within the standard for this
type of studies.
2.7 Randomization and blinding
A random allocation scheme in which each participant has equal likelihood of being assigned
to treatment versus placebo groups (ratio 1:1:1) was used. The CRO (FLS Research Support)
generated an allocation list by blocks using numbers drawn from the uniform distribution.
Allocation was performed considering the stratification for TST-positive and TST-negative.
Treatment is masked, meaning that neither the investigator nor the volunteer knows if the
vial contains NR or Placebo. Both treatments were physically identical with the same excipi-
ents. Labelling was also identical, indicating the study code, the numerical identification of the
subject and the data referred to the promoter, administration route and posology.
In an emergency case that would require to open the double blind, the researcher had to
contact to the CRO which would inform the composition of the treatment of the subject. The
investigator had to write a justification explaining the reasons for opening the double blind.
Investigational treatment kits were conserved in UTE and transferred to the Phase I Unit
until their use. Both places performed temperature log on a daily basis.
2.8 Statistical methods
Results were expressed as median with the interquartile range (IQR), or as otherwise specified.
All the analyses corresponding to the demographic variables, basal characteristics, as well as
the variables to evaluate the Immunogenicity were made with the population per protocol (all
randomized subjects who met the selection criteria, received the study treatment, and did not
present major protocol deviations). All the analyses corresponding to the security variables
were carried out in the safety population (all participants who received at least ten doses of the
treatment).
Continuous variables were compared using non parametrical tests, Mann-Whitney and
Kruskal-Wallis for non-paired and Wilcoxon test for paired data. The Chi-square or Fisher’s
exact test, as appropriate according to the variables distribution, was used to compare categori-
cal variables. Given the exploratory nature of this study of phase I, no multiplicity adjustments
were considered. The analysis was performed using SPSS(1) v. 15 (SPSS Inc., Chicago, IL,
USA) and the level of significance was established at the 0.05 level (two-sided).
3 Results
3.1 Participant flow and recruitment
The CT lasted 5 months (from 31th of March to 29th of August 2014) from the data the first
participant enrolled to the time the last participant finished. After screening a total of 76 volun-
teers during the whole CT, 51 were included and randomized. A total of 25 volunteers were
excluded for not fulfilling the study’s requirements: presenting hematologic abnormalities
such as anaemia (3 participants) or thrombocytopenia (2), vaccinated 3 months before the CT
Safety and immunogenicity of the supplement food Nyaditum resae®
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(2), and having an autoimmune disease (1). Recent vaccination and autoimmune disease were
excluded as considered able to interfere with the immunological results. After groups with
negative TST were completed, 14 screened participants had a TST negative result, and thus
were not included. And finally, 3 participants were excluded because the recruitment period
was promptly ended (Fig 1).
The other 51 volunteers were included and randomized. Eighteen participants were in the
placebo group, 17 in the high dose NR and 16 in the low dose NR group.
Each volunteer was treated with the allocated intervention (NR or placebo) and followed-
up for a total of 6 weeks. No loss of follow-up or discontinuation of the treatment occurred,
with the all 51/51 volunteers being analysed at the end of the CT. None of the subjects included
in the present CT decided to withdraw from the study, nor was removed by the investigators.
All volunteers declared to take the whole treatment (14 vials on a daily basis).
All the results and data obtained from the volunteers during the whole study are considered
confidential. Furthermore, the investigator’s team certifies that to their knowledge all subjects
were healthy and thus considered able to be included in the CT, in terms of fulfilling all the
study’s requirements.
The only protocol deviation from the study protocol occurred was the recruitment
promptly stopped because the TST reagent (PPD RT-23) was out of stock (http://www.aemps.
gob.es/informa/notasInformativas/medicamentosUsoHumano/problemasSuministro/2014/
NI-MUH_20-2014-tuberculina.htm), resulting in a smaller sample size than expected (n = 60)
in the TST-positive groups.
3.2 Baseline data
All demographic and clinical baseline characteristics for the 51 volunteers finally included in
the CT, with the corresponding ratio or median with the interquartile range (IQR), are sum-
marized in Table 2.
The anamnesis and physical exams performed to the volunteers during screening did not
show any clinical significant abnormality. The results of the laboratory analysis of all the vol-
unteers included in the study performed during the screening were in the normal range; other-
wise, the investigators considered them without clinical significance.
3.3 Outcomes and estimation
3.3.1 Results of laboratory tests. The abnormal laboratory tests possibly or probably
related to the investigational treatment recorded during the CT include kidney function,
Table 2. Demographic characteristics of the clinical trial.
Placebo (n = 18) Nyaditum resae® low dose (n = 16) Nyaditum resae® high dose (n = 17)
Age (years)* 25.5 (22–36.3) 31 (23–44.3) 29 (21.5–42.5)
Gender (% men) 28% 43.80% 52.90%
Underlying disease (% yes) 88.90% 93.80% 94.10%
Height (cm)* 165.5 (160.5–170.3) 169.0 (162.5–175.3) 171.0 (163.5–179.5)
Weight (kg)* 65.7 (51.8–79.9) 70.1 (58.8–80.8) 67.4 (61.5–81.5)
Systolic blood pressure (mm Hg)* 111 (102–122) 116 (103–141) 113 (106–123)
Diastolic blood pressure (mm Hg)* 64 (58–67) 65 (58–77) 63 (59–69)
Cardiac frequency* 69 (60–79) 64 (57–72) 68 (60–75)
Respiratory frequency* 18 (16–20) 20 (17–20) 18 (13–21)
* median (IQR)
doi:10.1371/journal.pone.0171294.t002
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hepatic enzymes, haematology and glycemia. No significant statistical differences were found
when compared between groups (Table 3).
Seven participants (13.7%) presented an increase of bilirubin or transaminase values. All of
the elevations were asymptomatic, mild and resolved in the following weeks or at the end of
the trial.
Five participants (9.8%) presented a decrease of haemoglobin or an abnormal value of leu-
cocytes, all of them were also asymptomatic, mild and resolved in the following weeks or at the
end of the trial (excepting one volunteer in the placebo group with a probably myeloprolifera-
tive syndrome currently in study). A participant presented a moderate thrombocytopenia that
spontaneously resolved within 5 weeks.
Hyperglycemia was recorded in 2 participants and hypoglycemia in one. These were also
asymptomatic, mild and resolved in the following weeks or at the end of the trial.
3.3.2 Physical examination and vital signs. No anomalies regarding to vital signs were
detected during the trial visits.
3.3.3 Adverse events. The 51 participants reported a total of 322 AE. The 92.5% (298) of
the AE were mild, and only one was classified as severe but was considered improbably to be
related to the investigational treatment (radial bone fracture after slipping and falling). No sta-
tistical differences were found when comparing the median (IQR) number of AE between the
placebo group and both treatment groups (Table 4).
The 46.3% (149/322) of the overall reported AE were considered possibly or probably
related to the investigational treatment. No AE were causally related as definite. The 47% of
the AE probably or possibly related to the treatment (70/149) occurred in the placebo group,
29.5% (44/149) in the NR low dose group, and 23.5% (35/149) in the NR high dose group.
None of them were severe (94% were mild and 6% moderate). The most common reported AE
were gastrointestinal events (82%, 122/149).
The 78.4% (40/51) of the participants presented at least one gastrointestinal event (no sig-
nificant differences were found between treatment groups, p = 0.078), reporting most fre-
quently mild abdominal pain and/or increase of the stool frequency (in 35.3% of the
participants each one [18/51]) (Table 3).
3.3.4 Imunogenicity assays. According to the work of Dwyer [26] differential expression
of CD25 and CD39 on circulating CD4+ T cells distinguishes between memory Treg (CD25
+CD39+) and pathogenic cellular populations that secrete proinflammatory cytokines such as
IL-17 (CD25-CD39+) and that an increase in the latter population is related with a decrease
on the Treg population. Our data in the TB murine model of TB demonstrate that the evolu-
tion from LTBI to TB is also related to an increase of this CD25-CD39+ T cell population
through the production of IL-17 [22]. FACS analysis strategy used allowed us to identify 4 dif-
ferent types of cells. CD25+CD39-: mainly effector Tregs (80–90%); CD25+CD39+: memory
Tregs; CD25-CD39-: Non Treg Effector cells; CD25-CD39+: ex-Treg cells mainly IL-17
producers.
Figs 3, 4 and 5 show the evolution of the PPD stimulated cells. Essentially both TST-nega-
tive and TST-positive volunteers treated with NR experimented a global increase on Treg
response, showed in both populations of CD25+CD39-, mainly effector Treg cells or CD25
+CD39+ memory Treg cells, according to different authors [26,29].
Furthermore, the levels of Tregs were in general higher in TST-positive subjects during and
after the treatment, being the group treated with the high dose NR the one that experienced
more significant increases with time (Fig 6). Indeed, in the group of TST-positive subjects
treated with placebo the baseline levels were really high and stable, probably reflecting an
already protected population. In some cases a significant decrease in the CD25-CD39+ popula-
tion has also been noted.
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Protection index as assayed by Dwyer [26] was also determined as a ratio between the data
obtained by the ratio of stimulated and non-stimulated CD25+CD39+ and CD25-CD39+
cells. In this case, even when naturally Placebo groups can have increased levels of Tregs, only
NR treated groups experienced an increase in this index, maybe relating to a “real” protection,
or at least a better cellular distribution able to avoid a pro-inflammatory milieu. The levels
were higher in TST-positive volunteers and after being treated with the highest dose of NR
(Fig 7).
Table 4. Comparison of the median (IQR) number of AE by groups.
Gastrointestinal Non-Gastrointestinal Total
Placebo 4 (2–6) 2 (1–3) 6 (4–9)
Nyaditum resae® low dose 2.5 (1.3–4) 2 (1.3–4.5) 4.5 (4–9)
Nyaditum resae® high dose 2 (1.0–3.5) 2 (1–4.5) 5 (2.5–7.5)
P-value 0.057 0.444 0.467
doi:10.1371/journal.pone.0171294.t004
Fig 3. Evolution of the PPD-stimulated T cells in all volunteers regardless their TST status. Treatment groups are represented in black, red and
blue, corresponding to Placebo, low dose and high dose Nyaditum resae® respectively. P- values calculated by Wilcoxon matched pairs test. Plots are
shown with median, IQR and minimum/maximum values.
doi:10.1371/journal.pone.0171294.g003
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4 Discussion
The objectives of this CT were to demonstrate the safety of the new product Nyaditum resae1
and evaluate its effect on specific Regulatory T cells (Treg) cells population.
Surprisingly, the median number of AE in placebo treated participants was higher than in
groups treated with the investigational treatment, but no significant differences were found
when comparing between groups. More than two-thirds of participants presented a gastroin-
testinal event with a similar distribution between groups. Gastrointestinal adverse events are
very unspecific and usually frequent when the investigational treatment is administered orally.
Moreover, gastrointestinal events were those we could mainly expect because of administra-
tion route (oral) as well as the bacterial origin of the probiotic. As all the participants were
informed about this potential effect, this could explain the high rate of AE considered
probably and possibly. On the other hand, it is well known that the administration of placebo
can induce AE, related to the informed potential AE of the investigational product. It is logical
then the fact that placebo side effect profile is mostly similar to the side effect profile of the
Fig 4. Evolution of the PPD-stimulated T cells in TST-negative volunteers. Treatment groups are represented in black, red and blue, corresponding
to Placebo, low dose and high dose Nyaditum resae® respectively. P- values calculated by Wilcoxon matched pairs test. Plots are shown with median,
IQR and minimum/maximum values.
doi:10.1371/journal.pone.0171294.g004
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investigational treatment [30]. Variability on the adverse events profile in healthy volunteers
has been related to personality and lifestyle of volunteers. Although randomisation, women
were more frequent in the placebo group than in the investigational treatment groups. Somati-
zation and hypocondriacal features, and adverse reaction in general, are predominantly related
to women [31], which could explain the highest incidence in this group.
Laboratory abnormalities such as liver or glycemia alterations were more frequent in the
probiotic groups than placebo, without significant differences found. Contrary to these alter-
ations, leucocytes abnormalities were more frequent in the placebo groups, also without signif-
icant differences. The small sample size of this study is a limitation and could difficult the
possibility to find statistical significant differences between groups. A bigger sample size could
be necessary to elucidate the incidence and relation to treatment of those rare AE.
In the present clinical trial we have demonstrated the safety of the NR, because, although
the AE were frequent, they were mild and spontaneously resolved within the following weeks,
and no significant differences were found when compared between groups.
Fig 5. Evolution of the PPD-stimulated T cells in TST-positive volunteers. Treatment groups are represented in black, red and blue, corresponding to
Placebo, low dose and high dose Nyaditum resae® respectively. P- values calculated by Wilcoxon matched pairs test. Plots are shown with median, IQR
and minimum/maximum values.
doi:10.1371/journal.pone.0171294.g005
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Data provided show for the first time that the administration of low doses of heat-killed
non tuberculous mycobacteria is able to induce both effector and memory specific Tregs. The
induction of Tregs by probiotics is well known [32] even when using heat-killed probiotics
[33]. It has been recently demonstrated that in some cases the effect induced by probiotics is
not affected by its viability [34], emerging the concept of “paraprobiotic” or “ghost probiotics”
[35] which have clear advantages in terms of production, stability and security of the product.
Shinkai et al [36] have recently evaluated the usefulness of the oral intake of heat-killed Lacto-
bacillus pentosus strain b240 as immunoprotective by reducing the incidence rate of the com-
mon cold in elderly adults. Previously, Zhang et al [37] demonstrated that the administration
of heat-killed Enterococcus faecalis FK-23 was able to attenuate the Th17 response in the lung,
thus suppressing the allergic response in a murine model of asthma induced by ovalbumin.
Recently it has been demonstrated that IL-17 plays a paramount role in the evolution from
infection to disease in a TB model in mice, by increasing the inflammatory response in the
granuloma through a neutrophilic infiltration, followed by the coalescence of different lesions
[8,9,22]. Furthermore, it has been demonstrated that mice from a strain that never develops
TB had higher levels of Tregs and when these mice were treated with mAbs anti CD25 for the
Tregs depletion, TB appeared [22].
Fig 6. Evolution of the PPD-stimulated T cells according to TST status. Comparison between TST-negative and TST-positive volunteers.
Treatment groups are represented in black, red and blue, corresponding to Placebo, low dose and high dose Nyaditum resae® respectively. P- values
calculated by Mann Whitney test, expressed in intervals: * from 0.05 to 0.01; ** from <0.01 to 0.001 and *** <0.001. Plots are shown with median, IQR
and minimum/maximum values.
doi:10.1371/journal.pone.0171294.g006
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After the induction of a low dose tolerance with a daily oral administration of heat killed
mycobacteria, progression towards TB was abrogated as demonstrated by increasing from 30
to 50% the survival time of the mice. When translating this phenomenon to humans, another
local defence mechanism not present in mice must be taken into account: the septae that sur-
rounds secondary lung lobules able to encapsulate lesions and abrogate its growth [38].
So far, the induction of Tregs after Mtb infection has been understood as deleterious. Tregs
have been claimed to be responsible for a weaker cellular immune response, stopping Th1 cel-
lular proliferation [29] that would fuel the progression from LTBI to TB [39,40], and inducing
a limited protection after BCG vaccination [41]. Further investigations have given them a neu-
tral role [42–44] mostly in models where protection was measured through the reduction of
the bacillary load. Recently, when also evaluating the role of the pathology, some authors have
seen a protective role of the presence of Tregs linked to a control of the inflammatory response
[45].
The presence of M. fortuitum complex bacilli in the tap water has been demonstrated by dif-
ferent authors in different regions of the planet [46–51] including the region where the clinical
trial was run [52]. This was the reason for developing NR as a supplement food once an equiv-
alent protective effect than the induced by the HKMtb was demonstrated [22]. On the other
hand this fact might had played a role in our trial as there was a risk that subjects from the pla-
cebo group had drank tap water with M. fortuitum bacilli, or even that treatment with the
investigation product boosted the immune response of subjects that has been previously in
contact with this bacillus. When designing the trial, we assumed to include this risk, as it is
part of real life.
NR has also demonstrated its capacity to induce specific Tregs and also memory Tregs
(CD39+). Overall, the highest dose was more clearly related to an increase of this cell population.
Fig 7. Protection index as assayed after Dwyer [26] determined as a ratio between the data obtained by the ratio of
stimulated and non-stimulated CD25+CD39+ and the obtained by the ratio of stimulated and non-stimulated
CD25-CD39+ cells. Results divided according TST status: (A) TST-positive, (B) TST-negative. Treatment groups are
represented in black, red and blue, corresponding to Placebo, low dose and high dose Nyaditum resae® respectively. P-
values calculated by Wilcoxon matched pairs test. Plots are shown with median, IQR and minimum/maximum values.
doi:10.1371/journal.pone.0171294.g007
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TST status has also shown to play a major role. TST positive participants had in general more
Tregs than TST-negative, both in Placebo or NR treated subjects. This fact was expected because
Mtb infection itself also induces the presence of Tregs. Interestingly, the Placebo group of TST-
positive subjects had a very high number of Tregs from the baseline, although it did not experi-
ment any increase during the clinical trial. In this regard we could theorize that those subjects
have already been protected, and it can be hypothesized that this is either because they have had
contact with non-tuberculosis mycobacteria or because the Mtb infection has naturally triggered
a higher proportion of Tregs in those volunteers. This latter hypothesis would be in concordance
with the concept of genetic resistance [53,54]. In fact, in our experience, we have been able to
demonstrate higher Treg % in those mice strains that better resist the Mtb infection (data not
published).
Regarding the data presented to monitor Treg response, we mainly presented raw data of
PPD stimulated PBMCs, following the methodology of other authors [28] that have observed a
better response-window. In fact, non-stimulated PBMCs have shown very low levels of Tregs
through time in all treatment groups. When we analysed the protection ratio as a measure
of protection firstly described by Dwyer et al [26], we have been able to show a significant
increase through time in the group of the highest dose of NR (105 CFU) in both TST-positive
and negative participants.
In conclusion, data supports that the administration of Nyaditum resae1, a product based
on heat killed bacilli of Mycobacterium manresensis, is able to induce a specific increase of the
Treg response including memory cells, with an excellent safety profile, thus being a new tool to
reduce the risk of the progression from latent infection to TB in humans.
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